ArticleEndocrine2019
Circulating microRNA-144-3p and miR-762 are novel biomarkers of Graves' disease.
Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Deletion of miR-122-5p Exacerbated Hyperthyroidism-Induced Liver Injury by Regulating Ferroptosis.International journal of endocrinology · 2026Article
- Epigenetic Mechanisms in Autoimmune Thyroid Diseases: Bridging Research and Clinical Applications.International journal of molecular sciences · 2025Review
- The Role of miRNA in Hyperthyroidism Induced by Excessive Iodine in Drinking Water.Biological trace element research · 2025Article
- The Use of Tissue-on-Chip Technology to Focus the Search for Extracellular Vesicle miRNA Biomarkers in Thyroid Disease.International journal of molecular sciences · 2023Article
- MiR-29a-3p negatively regulates circulating Tfh memory cells in patients with Graves' disease by targeting ICOS.Immunologic research · 2023Article
- Serum microRNA as a potential biomarker for the activity of thyroid eye disease.Scientific reports · 2023Article
- Regulatory mechanisms of microRNAs in endocrine disorders and their therapeutic potential.Frontiers in genetics · 2023Review
- Upregulation of microRNA-762 suppresses the expression of GIPC3 in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus.Immunity, inflammation and disease · 2022Article
- Landscape of immune infiltration in entorhinal cortex of patients with Alzheimer's disease.Frontiers in pharmacology · 2022Article
- Genetics, Epigenetics, Cellular Immunology, and Gut Microbiota: Emerging Links With Graves' Disease.Frontiers in cell and developmental biology · 2021Review
- miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.BMC cancer · 2019Article
- Identification of Circulating miR-762 as a Novel Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
purposeRecently, it has been confirmed that circulating miRNAs play an important role in disease pathogenesis and can be biomarkers of many autoimmune diseases. However, the knowledge about circulating miRNAs in Graves' disease (GD) is very limited. In this study, we aimed to identify circulating miRNAs as potential biomarkers of GD.
methodsWe recruited 68 participants who met the criteria for GD and healthy controls. The expression profile of miRNAs in plasma was detected using microarrays. We found five interesting miRNAs were differentially expressed between GD and control group and futher validated their relative expression by quantitative real-time PCR. According to their putative target genes predicted by the TargetScan database, we also performed Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analyses to predict their potential functions and related pathways.
resultsMicroarray data showed that five miRNAs were differentially expressed in GD and control plasma samples. Among them, miR-16-1-3p, miR-122-5p, miR-221-3p, and miR-762 were upregulated in GD (P < 0.001). In validation stage, we found miR-144-3p was significantly decreased and miR-762 was markedly upregulated in GD plasma (P < 0.01). In addition, miR-762 expression was positively associated with levels of FT3 (r = 0.307, P = 0.038) as well as TRAb (r = 0.302, P = 0.042). The receiver-operating characteristic (ROC) curve analysis showed that both miR-144-3p and miR-762 displayed good sensitivity and specificity in discriminating the GD patients from the rest of subjects with the area under the ROC curve (AUC) of 0.761 (P = 0.001, 95% CI = 0.648-0.875) and 0.737 (P = 0.001, 95% CI = 0.618-0.857), respectively. Combination of miR-144-3p and miR-762 could better discriminate GD patients from healthy controls with AUC of 0.861 (P < 0.001, 95% CI = 0.775-0.947).
conclusionsWe first demonstrated that aberrant levels of plasmic miR-144-3p and miR-762 were associated with GD, which may be biomarkers for GD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.